研究者データベース

朝野 拓史(アサノ ヒロシ)
北海道大学病院 小児・周産・女性科
助教

基本情報

所属

  • 北海道大学病院 小児・周産・女性科

職名

  • 助教

学位

  • 博士(医学)(2020年03月 北海道大学)

科研費研究者番号

  • 60880052

ORCID ID

J-Global ID

研究分野

  • ライフサイエンス / 産婦人科学

職歴

  • 2021年04月 - 現在 北海道大学病院 産科 助教
  • 2020年04月 - 2021年03月 北海道大学 大学院医学研究科 特任助教

研究活動情報

論文

  • Hiroshi Asano, Katsutoshi Oda, Kosuke Yoshihara, Yoichi M Ito, Noriomi Matsumura, Muneaki Shimada, Hidemichi Watari, Takayuki Enomoto
    Journal of gynecologic oncology 33 4 e55  2022年05月03日 
    BACKGROUND: Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma (uLMS) have HRD, including 7.5%-10% of BRCA1/2 alterations and 4%-6% of carcinomas of the uterine corpus, and 2.5%-4% of the uterine cervix have alterations of BRCA1/2. Preclinical and clinical case reports suggest that PARP inhibitors may be effective against those targets. The Japanese Gynecologic Oncology Group (JGOG) is now planning to conduct a new investigator-initiated clinical trial, JGOG2052. METHODS: JGOG2052 is a single-arm, open-label, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of niraparib monotherapy for a recurrent or persistent rare fraction of gynecologic malignancies with BRCA1/2 mutations except for ovarian cancers. We will independently consider the effect of niraparib for uLMS or other gynecologic malignancies with BRCA1/2 mutations (cohort A, C) and HRD positive uLMS without BRCA1/2 mutations (cohort B). Participants must have 1-3 lines of previous chemotherapy and at least one measurable lesion according to RECIST (v.1.1). Niraparib will be orally administered once a day until lesion exacerbation or unacceptable adverse events occur. Efficacy will be evaluated by imaging through an additional computed tomography scan every 8 weeks. Safety will be measured weekly in cycle 1 and every 4 weeks after cycle 2 by blood tests and physical examinations. The sample size is 16-20 in each of cohort A and B, and 31 in cohort C. Primary endpoint is the objective response rate. TRIAL REGISTRATION: Japan Primary Registries Network (JPRN) Identifier: jRCT2031210264.
  • Yosuke Konno, Hiroshi Asano, Ayumi Shikama, Daisuke Aoki, Michihiro Tanikawa, Akinori Oki, Koji Horie, Akira Mitsuhashi, Akira Kikuchi, Hideki Tokunaga, Yasuhisa Terao, Toyomi Satoh, Kimio Ushijima, Mitsuya Ishikawa, Nobuo Yaegashi, Hidemichi Watari
    Journal of gynecologic oncology 32 2 e25  2021年03月 [査読有り]
     
    OBJECTIVES: This review aims to introduce preoperative scoring systems to predict lymph node metastasis (LNM) and ongoing clinical trials to investigate the therapeutic role of lymphadenectomy for endometrial cancer. METHODS: We summarized previous reports on the preoperative prediction models for LNM and evaluated their validity to omit lymphadenectomy in our recent cohorts. Next, we compared characteristics of two ongoing lymphadenectomy trials (JCOG1412, ECLAT) to examine the survival benefit of lymphadenectomy in endometrial cancer, and described the details of JCOG1412. RESULTS: Lymphadenectomy has been omitted for 64 endometrial cancer patients who met low-risk criteria to omit lymphadenectomy using our scoring system (LNM score) and no lymphatic failure has been observed. Other two models also produced comparable results. Two randomized phase III trials to evaluate survival benefit of lymphadenectomy are ongoing for endometrial cancer. JCOG1412 compares pelvic lymphadenectomy alone with pelvic and para-aortic lymphadenectomy to evaluate the therapeutic role of para-aortic lymphadenectomy for patients at risk of LNM. For quality assurance of lymphadenectomy, we defined several regulations, including lower limit of the number of resected nodes, and submission of photos of dissected area to evaluate thoroughness of lymphadenectomy in the protocol. The latest monitoring report showed that the quality of lymphadenectomy has been well-controlled in JCOG1412. CONCLUSION: Our strategy seems reasonable to omit lymphadenectomy and could be generalized in clinical practice. JCOG1412 is a high-quality lymphadenectomy trial in terms of the quality of surgical procedures, which would draw the bona-fide conclusions regarding the therapeutic role of lymphadenectomy for endometrial cancer.
  • Michinori Mayama, Hiroshi Asano, Eiji Nomura, Kei Ihira, Ayako Nozaki, Tatsuya Kato, Yousuke Konno, Takashi Mitamura, Noriko Kobayashi, Mahito Takeda, Masataka Kudo, Hidemichi Watari
    Japanese journal of clinical oncology 50 8 882 - 888 2020年08月04日 [査読有り][通常論文]
     
    OBJECTIVE: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles. METHODS: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Baseline patient's background differences were assessed with inverse probability of treatment weighting using propensity score. RESULTS: Overall and disease-free survivals between the two groups were not significantly different. Paclitaxel + carboplatin, every 3-4 weeks was the most frequently used chemotherapy regimen in both groups. Patients in the six-cycle chemotherapy group developed neutropenia G4 or febrile neutropenia more frequently than those in the four-cycle group; odds ratio (95% confidence interval) is 4.07 (1.51-10.96). Peripheral sensory neuropathy was the most frequently observed non-hematological toxicity; the incidence of peripheral sensory neuropathy was not significantly different between four- and six-cycle chemotherapy group, P = 0.832. The result was same in the subgroup analysis in patients who received TC regimen, P = 0.455. CONCLUSION: This study implies a possible benefit of fewer cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence because of the lower incidence of hematological toxicities without impairing survival outcomes.
  • Hiroshi Asano, Kanako C Hatanaka, Ryosuke Matsuoka, Peixin Dong, Takashi Mitamura, Yosuke Konno, Tatsuya Kato, Noriko Kobayashi, Kei Ihira, Ayako Nozaki, Akira Oku, Yoshihiro Matsuno, Yutaka Hatanaka, Hidemichi Watari
    Annals of surgical oncology 27 7 2159 - 2168 2020年07月 [査読有り][通常論文]
     
    BACKGROUND: L1 cell adhesion molecule (L1CAM) has been established as an important predictor of poor survival of early-stage endometrial cancer patients. We investigated whether L1CAM remains a significant predictor of poor survival of patients with advanced-stage endometrial cancer undergoing extensive surgical staging and adjuvant chemotherapy. METHODS: We prepared tissue microarray (TMA) from surgical tissue specimens of 161 endometrial cancer patients who underwent full lymphadenectomy combined with adjuvant chemotherapy for patients at risk for recurrence, and evaluated expression of L1CAM using immunohistochemistry. The correlation between L1CAM positivity and clinicopathological factors and the prognostic significance of L1CAM expression was investigated. RESULTS: Among 161 cases who had a follow-up duration of over 3 years, 48 cases (29.8%) showed positive staining for L1CAM. L1CAM positivity was significantly correlated with non-endometrioid histology (p < 0.0001), vascular invasion (p = 0.0157), and positive cytology (p = 0.005), and was a significant predictor of poor survival among advanced-stage patients, but not early-stage patients in our cohort. L1CAM-positive patients showed a higher recurrence rate and frequency of distant failure than L1CAM-negative patients. Multivariate analysis revealed that para-aortic lymph node metastasis (PANM) and L1CAM positivity were independent predictors of poor survival. Overall survival can be stratified into three groups by the combination of PANM and L1CAM positivity. CONCLUSION: L1CAM is an independent predictor of poor survival in endometrial cancer patients undergoing full lymphadenectomy and adjuvant chemotherapy, thus indicating that L1CAM can be clinically used as a biomarker to identify those patients at increased risk of recurrence.
  • Hiraku Endo, Naoki Hama, Muhammad Baghdadi, Kozo Ishikawa, Ryo Otsuka, Haruka Wada, Hiroshi Asano, Daisuke Endo, Yosuke Konno, Tatsuya Kato, Hidemichi Watari, Akiko Tozawa, Nao Suzuki, Tomoyuki Yokose, Atsushi Takano, Hisamori Kato, Yohei Miyagi, Yataro Daigo, Ken-Ichiro Seino
    International immunology 32 3 175 - 186 2020年03月07日 [査読有り][通常論文]
     
    Ovarian cancer is the second-most lethal gynecological malignancy and the seventh-commonest cause of cancer-related death in women around the world. Most of the ovarian cancer patients are diagnosed at advanced stages and suffer from recurrence after primary cytoreductive surgery and standard first-line chemotherapy. Thus, the successful management of ovarian cancer patients requires the identification of factors that contribute to progression and relapse. Interleukin-34 (IL-34) is a novel cytokine that acts as a tissue-specific ligand of colony-stimulating factor-1 receptor (CSF-1R). In cancer, IL-34 exerts pro-tumorigenic functions that promote tumor growth, metastasis, angiogenesis, immune suppression and therapeutic resistance. In this study, we evaluate the impact of IL-34 on progression and survival of ovarian cancer patients. First, IL-34 was found to be expressed in several human ovarian cancer cell lines and cancer tissues from patients. The expression of IL-34 was enhanced by cytotoxic chemotherapy in ovarian cancer cell lines and cancer tissues from chemotherapy-treated ovarian cancer patients. Importantly, high IL-34 expression correlated with worse progression-free survival (PFS) and overall survival in different cohorts. The assessment of PFS based on a combination between IL34 expression and other related genes such as CSF1R and CD163 helped further to reach more statistical significance compared with IL34 alone. Furthermore, in the murine ovarian cancer cell HM-1 in vivo model, it was suggested that IL-34-derived tumor cells was correlated with tumor progression and survival by modulating the immune environment. Collectively, these findings indicate a possible correlation between IL-34 expression and disease progression in ovarian cancer patients and the mouse model.
  • Hiroshi Asano, Yukiharu Todo, Hidemichi Watari
    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 28 2 228 - 34 2016年04月 [査読有り][通常論文]
     
    The aim of this review is to address the current status of adjuvant chemotherapy alone in early-stage cervical cancer treatments in the literature. At present, the therapeutic effect of adjuvant chemotherapy alone after radical surgery (RS) has not yet been established, and radiation therapy (RT) or concurrent chemoradiotherapy (CCRT) is recommended as the standard adjuvant therapy after RS for early-stage cervical cancer in various guidelines. The main purpose of adjuvant therapy after RS, however, should be to reduce extrapelvic recurrence rather than local recurrence, although adjuvant RT or CCRT has survival benefits for patients with intermediate- or high-risk factors for recurrence. Moreover, several studies reported that adjuvant therapies including RT were associated with a higher incidence of complications, such as lymphedema, bowel obstruction and urinary disturbance, and a lower grade of long-term quality of life (QOL) or sexual functioning than adjuvant chemotherapy alone. The effect of adjuvant chemotherapy alone for early-stage cervical cancer with intermediate- or high-risk factors for recurrence were not fully investigated in prospective studies, but several retrospective studies suggest that the adjuvant effects of chemotherapy alone are at least similar to that of RT or CCRT in terms of recurrence rate, disease-free survival, or overall survival (OS) with lower incidence of complications. Whereas cisplatin based combination regimens were used in these studies, paclitaxel/cisplatin (TP) regimen, which is currently recognized as a standard chemotherapy regimen for patients with metastatic, recurrent or persistent cervical cancer by Gynecologic Oncology Group (GOG), had also survival benefit as an adjuvant therapy. Therefore, it may be worth considering a prospective randomized controlled trial (RCT) of adjuvant chemotherapy alone using TP regimen versus adjuvant RT as an alternative adjuvant therapy. Because early-stage cervical cancer is a curable condition, it is necessary that the therapeutic strategies should be improved with considering adverse events and QOL for long-term survivors.
  • Hiroshi Asano, Masanori Kaneuchi, Itsuko Furuta, Yukie Yamaya, Kanako C Hatanaka, Mahito Takeda, Yoshihiro Matsuno, Noriaki Sakuragi
    The journal of obstetrics and gynaecology research 40 5 1441 - 4 2014年05月 [査読有り][通常論文]
     
    Entamoeba histolytica is estimated to infect approximately 1% of the global population. In Japan, the prevalence of amebic dysentery has been increasing, with more than 800 patients newly diagnosed annually. However, genital infection with E. histolytica is uncommon even in endemic areas. We present a case of vaginitis caused by E. histolytica. A 50-year-old Japanese woman without history of overseas travel presented to a nearby clinic with increased vaginal discharge. She had hemorrhagic erosion at the uterine cervix with yellowish vaginal discharge, and was referred to our hospital for exclusion of malignancy. Cervical cytology revealed periodic acid-Schiff-positive protozoa not aggregating around squamous cells, and thus amebic vaginitis was suspected. We performed polymerase chain reaction (PCR) analyses and identified E. histolytica. The vaginitis was treated with metronidazole, and the disappearance of amebic protozoa was confirmed by cytology and PCR. Therefore, it may be important to obtain early diagnosis by cervical cytology and PCR.
  • Yoichi Noya, Koh-Ichi Seki, Hiroshi Asano, Yosuke Mai, Takahiro Horinouchi, Tsunehito Higashi, Koji Terada, Chizuru Hatate, Akimasa Hoshi, Prabha Nepal, Mika Horiguchi, Yuji Kuge, Soichi Miwa
    Toxicology 314 1 1 - 10 2013年12月06日 [査読有り][通常論文]
     
    Smoking is a major risk factor for atherosclerotic vascular diseases, but the mechanism for its genesis is unknown. We have recently shown that the gas phase of cigarette smoke (nicotine- and tar-free cigarette smoke extract; CSE) likely to reach the systemic circulation contains stable substances which cause cytotoxicity like plasma membrane damage and cell death in cultured cells, and also that the plasma membrane damage is caused through sequential activation of protein kinase C (PKC) and NADPH oxidase (NOX) and the resulting generation of reactive oxygen species (PKC/NOX-dependent mechanism), whereas cell death is caused through PKC/NOX-dependent and -independent mechanisms. To identify these stable substances, the CSE was prepared by passing the main-stream smoke of 10 cigarettes through a Cambridge glass fiber filter, trapping of the smoke in a vessel cooled at -80°C, and subsequent dissolution in 10ml of water. The CSE was fractionated into nine fractions using reversed-phase HPLC, and each fraction was screened for cytotoxicity in cultured cells, using propidium iodide uptake assay for cell membrane damage and MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reduction assay for cell viability. The cytotoxicity was positive in two of the nine fractions (Fr2 and Fr5). After extraction of the active fractions into dichloromethane, GC/MS analysis identified 2-cyclopenten-1-one (CPO) in Fr5 but none in Fr2. After derivatization of the active fractions with O-(2,3,4,5,6-pentafluorobenzyl) hydroxylamine hydrochloride, GC/MS analysis identified acrolein, acetone and propionaldehyde in Fr2, and methyl vinyl ketone (MVK) in Fr5. After 4-h incubation, authentic acrolein and MVK induced concentration-dependent cytotoxicity with EC50 values of 75.9±8.2 and 47.0±8.0μM (mean±SEM; n=3), respectively, whereas acetone, propionaldehyde and CPO were without effect. However, after 24-h incubation, CPO induced concentration-dependent cytotoxicity with an EC50 value of 264.0±16.9μM (n=3). The concentrations of acrolein, MVK and CPO in the CSE were 3368±334, 2429±123 and 392.9±31.8μM (n=4), respectively, which were higher than the cytotoxic concentrations. The cytotoxicity of acrolein and MVK consisted of plasma membrane damage and decreased cell viability: the plasma membrane damage was totally prevented by treatment with an inhibitor of PKC or NOX, whereas the decreased cell viability was only partially prevented by these inhibitors. The cytotoxicity of CPO consisted only of decreased cell viability, which was totally resistant to these inhibitors. These results show that acrolein and MVK are responsible for the acute cytotoxicity of the CSE through PKC/NOX-dependent and -independent mechanisms, whereas CPO is responsible for the delayed cytotoxicity of the CSE through a PKC/NOX-independent mechanism.
  • Hiroshi Asano, Takahiro Horinouchi, Yosuke Mai, Osamu Sawada, Shunsuke Fujii, Tadashi Nishiya, Masabumi Minami, Takahiro Katayama, Toshihiko Iwanaga, Koji Terada, Soichi Miwa
    Journal of pharmacological sciences 118 2 275 - 87 2012年 [査読有り][通常論文]
     
    We examined cytotoxic effects of nicotine/tar-free cigarette smoke extract (CSE) on C6 glioma cells. The CSE induced plasma membrane damage (determined by lactate dehydrogenase leakage and propidium iodide uptake) and cell apoptosis {determined by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reduction activity and DNA fragmentation}. The cytotoxic activity decayed with a half-life of approximately 2 h at 37°C, and it was abolished by N-acetyl-L-cysteine and reduced glutathione. The membrane damage was prevented by catalase and edaravone (a scavenger of (•)OH) but not by superoxide dismutase, indicating involvement of (•)OH. In contrast, the CSE-induced cell apoptosis was resistant to edaravone and induced by authentic H(2)O(2) or O(2)(-) generated by the xanthine/xanthine oxidase system, indicating involvement of H(2)O(2) or O(2)(-) in cell apoptosis. Diphenyleneiodonium [NADPH oxidase (NOX) inhibitor] and bisindolylmaleimide I [BIS I, protein kinase C (PKC) inhibitor] abolished membrane damage, whereas they partially inhibited apoptosis. These results demonstrate that 1) a stable component(s) in the CSE activates PKC, which stimulates NOX to generate reactive oxygen species (ROS), causing membrane damage and apoptosis; 2) different ROS are responsible for membrane damage and apoptosis; and 3) part of the apoptosis is caused by oxidants independently of PKC and NOX.
  • Tsunaki Higa, Takahiro Horinouchi, Hiroyuki Aoyagi, Hiroshi Asano, Tadashi Nishiya, Arata Nishimoto, Ikunobu Muramatsu, Soichi Miwa
    Journal of pharmacological sciences 113 3 276 - 80 2010年 [査読有り][通常論文]
     
    The mechanism for sustained Ca2+ influx activated by G protein-coupled receptors was examined. In Chinese hamster ovary cells expressing recombinant human endothelin type B receptor (ET(B)R) and endogenous P2Y receptor (P2Y-R), endothelin-1 elicited a sustained Ca2+ influx depending on G(q/11 )protein, phospholipase C (PLC), Na+/H+ exchanger (NHE), and p38 mitogen-activated protein kinase (p38MAPK), whereas P2Y-R-induced sustained Ca2+ influx was negligible. Functional studies showed that NHE activation by ET(B)R was mediated via p38MAPK but not G(q/11)/PLC, while that by P2Y-R involves only G(q/11)/PLC/p38MAPK. These results suggest that G(q/11)/PLC-independent NHE activation via p38MAPK plays an important role in ET(B)R- mediated sustained Ca2+ influx.
  • Takahiro Horinouchi, Hiroshi Asano, Tunaki Higa, Arata Nishimoto, Tadashi Nishiya, Ikunobu Muramatsu, Soichi Miwa
    Journal of Pharmacological Sciences 111 4 338 - 351 2009年 [査読有り][通常論文]

その他活動・業績

  • 朝野 拓史, 渡利 英道 産婦人科の実際 = Obstetrical and gynecological practice 70 (5) 465 -471 2021年05月
  • L1CAMはsurgical stagingを受けた進行子宮体癌症例の独立予後不良因子である
    奥 聡, 朝野 拓史, 畑中 佳奈子, 松岡 亮介, 加藤 達矢, 金野 陽輔, 三田村 卓, 井平 圭, 野崎 綾子, 武田 真人, 小林 範子, 工藤 正尊, 松野 吉宏, 畑中 豊, 渡利 英道 北日本産科婦人科学会総会・学術講演会プログラム・抄録集 67回 49 -49 2019年09月 [査読無し][通常論文]
  • L1CAM陽性子宮体癌の臨床病理学的検討
    朝野 拓史, 畑中 佳奈子, 松岡 亮介, 小林 由佳子, 井平 圭, 野崎 綾子, 三田村 卓, 金野 陽輔, 加藤 達矢, 武田 真人, 小林 範子, 工藤 正尊, 畑中 豊, 松野 吉宏, 渡利 英道 日本婦人科腫瘍学会雑誌 37 (3) 499 -499 2019年06月 [査読無し][通常論文]
  • 胃癌の子宮頸部転移が疑われた1例
    前田 悟郎, 武田 真人, 奥 聡, 朝野 拓史, 小林 由佳子, 石塚 泰也, 丸川 活司, 今井 一章, 遠藤 大介, 岡田 宏美, 三田村 卓, 渡利 英道, 畑中 佳奈子, 櫻木 範明, 松野 吉宏 日本臨床細胞学会雑誌 56 (Suppl.2) 689 -689 2017年10月 [査読無し][通常論文]
  • 子宮体部粘液性腺癌の2例
    小林 由佳子, 武田 真人, 奥 聡, 朝野 拓史, 前田 悟郎, 石塚 泰也, 丸川 活司, 岡田 宏美, 三田村 卓, 保坂 昌芳, 畑中 佳奈子, 佐川 正, 渡利 英道, 櫻木 範明, 松野 吉宏, 今井 一章 日本臨床細胞学会雑誌 56 (Suppl.2) 718 -718 2017年10月 [査読無し][通常論文]
  • 子宮頸部絨毛腺管状腺癌の1例
    奥 聡, 武田 真人, 朝野 拓史, 今井 一章, 小林 由佳子, 前田 悟郎, 石塚 泰也, 丸川 活司, 岡田 宏美, 三田村 卓, 保坂 昌芳, 佐川 正, 渡利 英道, 畑中 佳奈子, 松野 吉宏 日本臨床細胞学会雑誌 56 (Suppl.2) 813 -813 2017年10月 [査読無し][通常論文]
  • MRIによる子宮体癌と子宮癌肉腫の鑑別に関する検討
    常田 慧徳, 加藤 扶美, 朝野 拓史, 野崎 綾子, 井平 圭, 三田村 卓, 金野 陽輔, 加藤 達矢, 渡利 英道, 飯嶋 由紀, 西岡 井子, 真鍋 徳子, 工藤 與亮 日本医学放射線学会秋季臨床大会抄録集 53回 S470 -S471 2017年08月 [査読無し][通常論文]
  • 卵巣明細胞腺癌に対するcabozantinibの抗腫瘍効果についての検討
    中谷 真紀子, 渡利 英道, 王 磊, 畑中 豊, 畑中 佳奈子, 西原 広史, 朝野 拓史, 遠藤 大介, 三田村 卓, 董 培新, シャロン・ハンリー, 田中 伸哉, 櫻木 範明 日本婦人科腫瘍学会雑誌 35 (3) 628 -628 2017年06月 [査読無し][通常論文]
  • 奥聡, 武田真人, 朝野拓史, 小林由佳子, 井平圭, 野崎綾子, 金野陽輔, 加藤達矢, 工藤正尊, 渡利英道, 清水亜衣, 松野吉宏 北日本産科婦人科学会総会・学術講演会プログラム・抄録集(Web) 65th (Suppl.) 134 (WEB ONLY) -73 2017年 [査読無し][通常論文]
  • 朝野 拓史, 渡利 英道 産婦人科の実際 65 (12) 1657 -1664 2016年11月 [査読無し][通常論文]
  • 朝野 拓史, 渡利 英道 産科と婦人科 83 (1) 39 -43 2016年01月 [査読無し][通常論文]
     
    子宮体癌に対する化学療法および分子標的治療に関する臨床試験をまとめた。現時点での標準化学療法レジメンは、術後補助化学療法ではAP療法、進行・再発癌ではそれに加えTAP療法やTC療法と考えられた。AP療法やTAP療法では毒性中止が高率である。しかし、分子標的薬単剤での効果は限定的であり、今後、新規レジメン(DP療法など)の検討およびTC療法とベバシズマブの併用療法の検討が期待される。(著者抄録)
  • 子宮体部明細胞腺癌の診断経過についての検討
    井平 圭, 朝野 拓史, 丸川 活司, 石塚 泰也, 岡田 宏美, 遠藤 大介, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 佐川 正, 畑中 佳奈子, 松野 吉宏, 櫻木 範明 日本臨床細胞学会雑誌 54 (Suppl.2) 558 -558 2015年10月 [査読無し][通常論文]
  • 婦人科分野におけるセルブロックの有用性の検討
    前田 悟郎, 朝野 拓史, 丸川 活司, 石塚 泰也, 井平 圭, 遠藤 大介, 岡田 宏美, 三田村 卓, 保坂 昌芳, 武田 真人, 渡利 英道, 佐川 正, 畑中 佳奈子, 松野 吉宏, 櫻木 範明 日本臨床細胞学会雑誌 54 (Suppl.2) 562 -562 2015年10月 [査読無し][通常論文]
  • 子宮体部に発生した小細胞癌の一例
    古田 祐, 朝野 拓史, 丸川 活司, 石塚 泰也, 前田 悟郎, 遠藤 大介, 三田村 卓, 武田 真人, 岡田 宏美, 藤澤 孝志, 渡利 英道, 佐川 正, 畑中 佳奈子, 松野 吉宏, 櫻木 範明 日本臨床細胞学会雑誌 54 (Suppl.2) 661 -661 2015年10月 [査読無し][通常論文]
  • 朝野 拓史, 武田 真人, 丸川 活司, 菅野 宏美, 畑中 佳奈子, 福本 俊, 井平 圭, 加藤 達矢, 保坂 昌芳, 渡利 英道, 櫻木 範明, 松野 吉宏 北海道臨床細胞学会会報 24 53 -56 2015年
  • 子宮頸部に進展した肺原発腺癌の一例
    朝野 拓史, 武田 真人, 丸川 活司, 渡利 英道, 金内 優典, 山田 洋介, 久保田 佳奈子, 佐川 正, 松野 吉宏, 櫻木 範明 日本臨床細胞学会雑誌 51 (Suppl.1) 392 -392 2012年03月 [査読無し][通常論文]
  • Yosuke Mai, Takahiro Horinouchi, Hiroshi Asano, Osamu Sawada, Tadashi Nishiya, Masabumi Minami, Takahiro Katayama, Koji Terada, Soichi Miwa JOURNAL OF PHARMACOLOGICAL SCIENCES 118 256P -256P 2012年 [査読無し][通常論文]
  • 赤痢アメーバ腟炎の1例
    朝野 拓史, 武田 真人, 山名 幸恵, 三田村 卓, 加藤 達矢, 渡利 英道, 金内 優典, 久保田 佳奈子, 松野 吉宏, 櫻木 範明 日本臨床細胞学会雑誌 50 (Suppl.1) 213 -213 2011年03月 [査読無し][通常論文]
  • 朝野 拓史, 山口 正博, 金野 陽輔, 加藤 達矢, 保坂 昌芳, 首藤 聡子, 古田 伊都子, 武田 真人, 渡利 英道, 金内 優典, 水上 尚典, 櫻木 範明 日本産科婦人科學會雜誌 63 (2) 719 -719 2011年
  • Takahiro Horinouchi, Tsunaki Higa, Hiroshi Asano, Arata Nishimoto, Tadashi Nishiya, Soichi Miwa JOURNAL OF PHARMACOLOGICAL SCIENCES 112 95P -95P 2010年 [査読無し][通常論文]
  • Takahiro Horinouchi, Tsunaki Higa, Hiroshi Asano, Tadashi Nishiya, Arata Nishimoto, Soichi Miwa JOURNAL OF PHARMACOLOGICAL SCIENCES 112 251P -251P 2010年 [査読無し][通常論文]

教育活動情報

主要な担当授業

  • 基本医学総論
    開講年度 : 2021年
    課程区分 : 修士課程
    開講学部 : 医学院
    キーワード : 妊娠の成立 妊娠・分娩の生理と病理
  • 医学総論
    開講年度 : 2021年
    課程区分 : 博士後期課程
    開講学部 : 医学院
    キーワード : 妊娠の成立 妊娠・分娩の生理と病理


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.